HealthEquity (NASDAQ:HQY) Downgraded by StockNews.com

StockNews.com cut shares of HealthEquity (NASDAQ:HQYGet Rating) from a hold rating to a sell rating in a report released on Tuesday.

Other equities research analysts have also issued research reports about the company. The Goldman Sachs Group upgraded HealthEquity from a sell rating to a neutral rating and raised their price objective for the company from $64.00 to $77.00 in a research note on Friday, October 21st. Robert W. Baird lifted their target price on HealthEquity from $47.00 to $67.00 and gave the stock a neutral rating in a research report on Wednesday, September 7th. Deutsche Bank Aktiengesellschaft lifted their target price on HealthEquity from $67.00 to $68.00 and gave the stock a buy rating in a research report on Thursday, September 8th. Wells Fargo & Company lifted their target price on HealthEquity from $100.00 to $104.00 and gave the stock an overweight rating in a research report on Tuesday, October 25th. Finally, Jefferies Financial Group lifted their target price on HealthEquity from $80.00 to $90.00 in a research report on Wednesday, November 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $77.64.

HealthEquity Stock Down 3.3 %

Shares of NASDAQ HQY opened at $61.72 on Tuesday. HealthEquity has a fifty-two week low of $36.81 and a fifty-two week high of $79.20. The business has a 50 day moving average price of $70.12 and a two-hundred day moving average price of $64.88. The firm has a market cap of $5.22 billion, a PE ratio of -83.41, a price-to-earnings-growth ratio of 3.46 and a beta of 0.87.

HealthEquity (NASDAQ:HQYGet Rating) last issued its quarterly earnings data on Tuesday, September 6th. The company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). HealthEquity had a negative net margin of 7.82% and a positive return on equity of 2.86%. The business had revenue of $206.14 million for the quarter, compared to analyst estimates of $203.40 million. During the same quarter last year, the business earned $0.21 EPS. On average, analysts anticipate that HealthEquity will post 0.69 earnings per share for the current year.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Ian Sacks sold 25,000 shares of HealthEquity stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $72.28, for a total transaction of $1,807,000.00. Following the sale, the director now owns 126,570 shares of the company’s stock, valued at approximately $9,148,479.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other HealthEquity news, Director Ian Sacks sold 25,000 shares of HealthEquity stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $72.28, for a total transaction of $1,807,000.00. Following the sale, the director now owns 126,570 shares of the company’s stock, valued at approximately $9,148,479.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Debra Charlotte Mccowan sold 4,225 shares of the business’s stock in a transaction on Tuesday, September 27th. The stock was sold at an average price of $70.91, for a total value of $299,594.75. Following the completion of the sale, the director now directly owns 7,072 shares in the company, valued at approximately $501,475.52. The disclosure for this sale can be found here. Insiders have sold 46,648 shares of company stock valued at $3,355,690 in the last quarter. Corporate insiders own 2.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HQY. SG Americas Securities LLC grew its stake in HealthEquity by 42.4% in the second quarter. SG Americas Securities LLC now owns 23,003 shares of the company’s stock valued at $1,412,000 after purchasing an additional 6,849 shares in the last quarter. Veritable L.P. acquired a new stake in shares of HealthEquity in the first quarter worth about $242,000. HighTower Advisors LLC lifted its position in shares of HealthEquity by 1.3% in the first quarter. HighTower Advisors LLC now owns 82,558 shares of the company’s stock worth $5,569,000 after buying an additional 1,029 shares during the last quarter. Woodline Partners LP lifted its position in shares of HealthEquity by 201.9% in the first quarter. Woodline Partners LP now owns 190,180 shares of the company’s stock worth $12,826,000 after buying an additional 127,188 shares during the last quarter. Finally, Stephens Inc. AR lifted its position in shares of HealthEquity by 12.5% in the first quarter. Stephens Inc. AR now owns 5,058 shares of the company’s stock worth $341,000 after buying an additional 562 shares during the last quarter. Hedge funds and other institutional investors own 99.43% of the company’s stock.

About HealthEquity

(Get Rating)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Read More

Analyst Recommendations for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.